PIK3CG and B-cell chronic lymphocytic leukemia: In a recent analysis of patient samples collected from trials involving various PI3K inhibitors, but mostly idelalisib, 60% of CLL patients who had no initial response to therapy have shown activating MAPK pathway mutations, which are specifically found in MAP2K1, KRAS and BRAF [361] Table 1.